RANK expression as a prognostic and predictive marker in breast cancer

Breast Cancer Research and Treatment

Volumn 145, Issue 2, 2014, Pages 307-315

  Pfitzner, Berit Maria ^a,g   Branstetter, Daniel ^b   Loibl, Sibylle ^c,i   Denkert, Carsten ^a,g   Lederer, Bianca ^c   Schmitt, Wolfgang Daniel ^a,g   Dombrowski, Frank ^d   Werner, Martin ^e,g   Rüdiger, Thomas ^f   Dougall, William C ^b   Von Minckwitz, Gunter ^c,h  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b AMGEN INC   (United States)

^c German Breast Group   (Germany)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f Karlsruhe Hospital   (Germany)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁱ SANA KLINIKUM OFFENBACH   (Germany)

Author keywords

Breast cancer; Denosumab; Immunohistochemistry; RANK

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; HORMONE RECEPTOR; NAVELBINE; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ADJUVANT THERAPY; BREAST NEOPLASMS; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 84901694948     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2955-1     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63(1):11-30. doi: 10.3322/caac.21166
2. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16(8):2672-2685 (Pubitemid 28363030)
3. Kaufmann M, von Minckwitz G, Rody A (2005) Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast 14(6):576-581 (Pubitemid 41683583)
4. Brown JE, Coleman RE (2012) Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol 9(2):110-118. doi: 10.1038/nrclinonc.2011.197
5. Roodman GD (2012) Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev 31(3-4):569-578. doi: 10.1007/s10555-012-9372-x
6. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM (2000) The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103(1):41-50
7. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468(7320):103-107. doi: 10.1038/nature09495
8. Dougall WC (2012) Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 18(2):326-335. doi: 10.1158/1078-0432.CCR-10-2507
9. Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-Ortega S, Urruticoechea A, Climent F, Soler MT, Munoz P, Vinals F, Tometsko M, Branstetter D, Dougall WC, Gonzalez-Suarez E (2012) RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res 72(11):2879-2888. doi: 10.1158/0008-5472.CAN-12-0044
10. Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R, Mochizuki S, Ikeda T, Mukai M, Okada Y (2009) Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol 218(4):530-539. doi: 10.1002/path.2567
11. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA (2006) Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107(2):289-298. doi: 10.1002/cncr.21978 (Pubitemid 44036558)
12. Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(Suppl 4):14-27. doi: 10.1634/theoncologist.9-90004-149/suppl-4/14 (Pubitemid 39363165)
13. Ford JA, Jones R, Elders A, Mulatero C, Royle P, Sharma P, Stewart F, Todd R, Mowatt G (2013) Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. Eur J Cancer 49(2):416-430. doi: 10.1016/j.ejca.2012.07.016
14. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M, On behalf of the German Breast G (2008) Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized gepartrio trial. J Natl Cancer Inst 100(8):542-551. doi: 10.1093/jnci/djn085
15. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Manfred K, For the German Breast G (2008) Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized gepartrio study. J Natl Cancer Inst 100(8):552-562. doi: 10.1093/jnci/djn089
16. von Minckwitz G, Blohmer JU, Raab G, Lohr A, Gerber B, Heinrich G, Eidtmann H, Kaufmann M, Hilfrich J, Jackisch C, Zuna I, Costa SD, German Breast G (2005) In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16(1):56-63. doi: 10.1093/annonc/mdi001 (Pubitemid 40124479)
17. von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Kummel S, Paepke S, Schneeweiss A, Untch M, Zahm DM, Mehta K, Loibl S (2013) Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 31(29):3623-3630. doi: 10.1200/JCO.2012.45.0940
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of NCIEWGoCD (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229-235. doi: 10.1007/s10549-006-9242-8 (Pubitemid 44631925)
19. Wood CE, Branstetter D, Jacob AP, Cline JM, Register TC, Rohrbach K, Huang LY, Borgerink H, Dougall WC (2013) Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res 15(4):R62. doi: 10.1186/bcr3456
20. Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C (2012) Cutoff Finder: A comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One 7(12):e51862. doi: 10.1371/journal.pone.0051862
21. von Minckwitz G, Müller BM, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Blohmer JU, du Bois A, Zahm DM, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, Denkert C (2011) Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 29(16):2150-2157. doi: 10.1200/JCO.2010.31.9079
22. Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, La Verde N, Caroti C, Treilleux I, Ruggiero A, Perrone G, Addeo R, Clezardin P, Muda AO, Tonini G (2011) Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One 6(4):e19234. doi: 10.1371/journal.pone.0019234
23. Zhang L, Teng Y, Zhang Y, Liu J, Xu L, Qu J, Hou K, Yang X, Liu Y, Qu X (2012) Receptor activator for nuclear factor κ B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis. J Clin Pathol 65(1):36-40. doi: 10.1136/jclinpath- 2011-200312
24. Blake ML, Tometsko M, Miller R, Jones JC, Dougall WC (2014) RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metastasis 31(2):233-245. doi: 10.1007/s10585-013-9624-3
25. Campbell JP, Karolak MR, Ma Y, Perrien DS, Masood-Campbell SK, Penner NL, Munoz SA, Zijlstra A, Yang X, Sterling JA, Elefteriou F (2012) Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol 10(7):e1001363. doi: 10.1371/journal.pbio.1001363
26. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470(7335):548-553. doi: 10.1038/nature09707
27. Sinn BV, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Tesch H, Kronenwett R, Hoffmann G, Belau A, Thommsen C, Holzhausen HJ, Grasshoff ST, Baumann K, Mehta K, Dietel M, Loibl S (2013) Evaluation of mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann Oncol 24(9):2316-2324. doi: 10.1093/annonc/mdt162
28. Loibl S, Muller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A, Fissler-Eckhoff A, Gerber B, Kulmer U, Alles JU, Mehta K, Denkert C (2011) Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 130(2):477-487. doi: 10.1007/s10549-011- 1715-8